Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
886 participants
INTERVENTIONAL
2005-12-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Levocetirizine
Levocetirizine, once daily, 4 week duration
Levocetirizine
5mg oral capsules, once daily, 4 week duration
Desloratadine
Desloratadine, once daily, 4 week duration
Desloratadine
5mg oral capsules, once daily, 4 week duration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levocetirizine
5mg oral capsules, once daily, 4 week duration
Desloratadine
5mg oral capsules, once daily, 4 week duration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- At visit 2 (after a baseline period of at least 3 days): patient with adequate signs of CIU, both in terms of symptoms and severity.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bruges, , Belgium
Brussels, , Belgium
Liège, , Belgium
Merksem, , Belgium
Sint-Niklaas, , Belgium
Woluwe-St-Lamb, , Belgium
Bernay, , France
Besançon, , France
Hyères, , France
Les Milles, , France
Marseille, , France
Montpellier, , France
Nancy, , France
Nantes, , France
Nice, , France
Nîmes, , France
Paris, , France
Poitiers, , France
Quimper, , France
Saint-Mandé, , France
Troyes, , France
Valence, , France
Villejuif, , France
Augsburg, , Germany
Berlin, , Germany
Cologne, , Germany
Dresden, , Germany
Düsseldorf, , Germany
Erlangen, , Germany
Göttingen, , Germany
Hamburg, , Germany
Hanover, , Germany
Leipzig, , Germany
Mahlow, , Germany
Mainz, , Germany
München, , Germany
Viersen, , Germany
Caserta, , Italy
Catania, , Italy
Cesena, , Italy
Genova, , Italy
Modena, , Italy
Palermo, , Italy
Pavia, , Italy
Roma, , Italy
Siena, , Italy
Udine, , Italy
Verona, , Italy
Johor Bharu, , Malaysia
Kelantan, , Malaysia
Kuala Lumpur, , Malaysia
Negeri Sembilan, , Malaysia
Perak, , Malaysia
Pulau Pinang, , Malaysia
Sarawak, , Malaysia
Brasov, , Romania
Bucharest, , Romania
Dolj, , Romania
Sibiu, , Romania
Cape Town, , South Africa
Durban, , South Africa
Lenasia, , South Africa
A Coruña, , Spain
Albacete, , Spain
Barcelona, , Spain
Granada, , Spain
Madrid, , Spain
Málaga, , Spain
Murcia (El Palmar), , Spain
Oviedo, , Spain
Santiago de Compostela, , Spain
Seville, , Spain
Valencia, , Spain
Amersham, , United Kingdom
Cardiff, , United Kingdom
Irvine, , United Kingdom
Leicester, , United Kingdom
London, , United Kingdom
Nuneaton, , United Kingdom
Salford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT 2005-000358-65
Identifier Type: -
Identifier Source: secondary_id
CUTE
Identifier Type: -
Identifier Source: secondary_id
A00394
Identifier Type: -
Identifier Source: org_study_id